Nicolaas Duneas | |
---|---|
Born | 1972 (age 51–52) |
Alma mater | University of the Witwatersrand |
Known for | bone regeneration |
Scientific career | |
Institutions | Altis Biologics |
Thesis | Synergistic Interactions of Bone Morphogenetic Protein and Transforming Growth Factor-β in Bone Induction and Regeneration (1998) |
Doctoral advisor | Ugo Ripamonti |
Website | Altis Biologics |
Nicolaas Duneas is a South African biochemist and developer of osteogenic biomaterials. [1] [2] He is the co-founder (with Nuno Pires) and CEO of Altis Biologics. [3] [4] The company developed the first injectable treatment for bone injuries that require grafting by using a pig-based growth material. [3]
Duneas received a BSc in biochemistry in 1993 from the University of the Witwatersrand (WITS) and he holds a MBA from WITS. [4] He also holds a Ph.D. from the WITS faculty of medicine. [3] From 1993 until 1997, he worked as research officer for the University of the Witwatersrand. [4]
In 2002, he founded Altis Biologics—a biotechnology company—together with Nuno Pires. [5] [6] Duneas was appointed CEO of Altis Biologics in 2002. [4]
The company focusses on bone regeneration. [5] Traditionally, when repairing a severe bone break involving a void, new bone is taken from the hip and donated to the required site. This results in permanent disfigurement of the hip and complications such as hip displacement, buttock anaesthesia and severe infections during surgery. Altis Biologics developed a method to use pig bone which had been altered to make it human compatible and also make it injectable, removing the need for surgery. [3] The method is particularly suitable for use in spinal fusion procedures. [6]
The research for this method began in 1994 and included pre-clinical and clinical studies (in collaboration with universities) that finally culminated in a product that was patented in 2006. In 2012 the method was approved by the largest South African medical aid (Discovery Health) and since then more than 1000 patients have been implanted with the bone graft. The tissue used in the bone grafts is manufactured in South Africa, removing the previous need to import bone graft material from the USA and Europe. [3]
From 2008 until 2010, Duneas also served as managing director of Altis Biologics. He has remained CEO since 2002. [4]
In 2014, Duneas was interviewed by Alec Hogg for The Rational Perspective (hosted on BizNews) on Sizing up African Technology Opportunities. [7] At the 2017 Healthcare Innovation Summit Africa he presented on bone regeneration technologies. [8]
In 2014, Duneas and Nuno Pires were awarded the Innovation Prize for Africa for the Altis Osteogenic Bone Matrix. This was the first injectable treatment for injuries requiring bone grafts using a porcine-derived regenerative biological implant. Duneas and Pires received US$100 000. [1] [9]
A growth factor is a naturally occurring substance capable of stimulating cell proliferation, wound healing, and occasionally cellular differentiation. Usually it is a secreted protein or a steroid hormone. Growth factors are important for regulating a variety of cellular processes.
Chondrocytes are the only cells found in healthy cartilage. They produce and maintain the cartilaginous matrix, which consists mainly of collagen and proteoglycans. Although the word chondroblast is commonly used to describe an immature chondrocyte, the term is imprecise, since the progenitor of chondrocytes can differentiate into various cell types, including osteoblasts.
Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabologens. Professor Marshall Urist and Professor Hari Reddi discovered their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. The important functioning of BMP signals in physiology is emphasized by the multitude of roles for dysregulated BMP signalling in pathological processes. Cancerous disease often involves misregulation of the BMP signalling system. Absence of BMP signalling is, for instance, an important factor in the progression of colon cancer, and conversely, overactivation of BMP signalling following reflux-induced esophagitis provokes Barrett's esophagus and is thus instrumental in the development of esophageal adenocarcinoma.
Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. Some small or acute fractures can be cured without bone grafting, but the risk is greater for large fractures like compound fractures.
Bone morphogenetic protein 7 or BMP7 is a protein that in humans is encoded by the BMP7 gene.
Bone morphogenetic protein 2 or BMP-2 belongs to the TGF-β superfamily of proteins.
Bone morphogenetic protein 4 is a protein that in humans is encoded by BMP4 gene. BMP4 is found on chromosome 14q22-q23.
Bone morphogenetic protein 8B is a protein that in humans is encoded by the BMP8B gene.
Bone morphogenetic protein 6 is a protein that in humans is encoded by the BMP6 gene.
Bone morphogenetic protein 5 is a protein that in humans is encoded by the BMP5 gene.
Bone morphogenetic protein 3, also known as osteogenin, is a protein in humans that is encoded by the BMP3 gene.
The bone morphogenetic protein receptor, type IA also known as BMPR1A is a protein which in humans is encoded by the BMPR1A gene. BMPR1A has also been designated as CD292.
Growth differentiation factor 2 (GDF2) also known as bone morphogenetic protein (BMP)-9 is a protein that in humans is encoded by the GDF2 gene. GDF2 belongs to the transforming growth factor beta superfamily.
Growth/differentiation factor 5 is a protein that in humans is encoded by the GDF5 gene.
Growth differentiation factor 10 (GDF10) also known as bone morphogenetic protein 3B (BMP-3B) is a protein that in humans is encoded by the GDF10 gene.
A fibrin scaffold is a network of protein that holds together and supports a variety of living tissues. It is produced naturally by the body after injury, but also can be engineered as a tissue substitute to speed healing. The scaffold consists of naturally occurring biomaterials composed of a cross-linked fibrin network and has a broad use in biomedical applications.
A. Hari Reddi is a University of California Distinguished Professor and holder of the Lawrence J. Ellison Endowed Chair in Musculoskeletal Molecular Biology at the University of California, Davis. His research played an indispensable role in the identification, isolation and purification of bone morphogenetic proteins (BMPs) that are involved in bone formation and repair.
Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRP where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue and is used as a tissue-engineering scaffold in oral and maxillofacial surgeries. PRF falls under FDA Product Code KST, labeling it as a blood draw/Hematology product classifying it as 510(k) exempt.
A bone growth factor is a growth factor that stimulates the growth of bone tissue.
Nuno Pires is a businessman from South Africa. He is the co-founder of Altis Biologics.